Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.50 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.49 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31183038 | 0.83 | HCAR3 (0.55) | FGFR1HDAC1ALDH1A1LMNAHPGD | |
| SCHEMBL2943641 | 0.83 | HDAC1 (0.53) | HTTKMT2APKMFGFR1HDAC1 | |
| SCHEMBL3436680 | 0.82 | HCAR3 (0.58) | FGFR1HDAC1ALDH1A1LMNAHPGD | |
| SCHEMBL30138443 | 0.82 | HCAR3 (0.58) | FGFR1HDAC1ALDH1A1LMNAHPGD | |
| SCHEMBL3816420 | 0.82 | HCAR3 (0.54) | FGFR1ALDH1A1LMNAHPGDF10 | |
| SCHEMBL30930540 | 0.80 | HPGD (0.68) | FGFR1ALDH1A1LMNAHPGDPLA2G4A | |
| SCHEMBL16148812 | 0.79 | HTT (0.60) | HTTKMT2APKMHDAC1F10 | |
| SCHEMBL708855 | 0.79 | HTT (0.68) | HTTKMT2APKMHDAC1CNOT7 | |
| SCHEMBL2996553 | 0.79 | HCAR3 (0.60) | FGFR1HDAC1ALDH1A1LMNAHPGD | |
| SCHEMBL31159882 | 0.79 | HCAR3 (0.56) | FGFR1ALDH1A1LMNAHPGDF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | YODA THERAPEUTICS INC. (TW) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | NLRP3, NOD1, NLRP1 | HTT 2343/4885KMT2A 4102/4885PKM 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.